Combination of mitoxantrone, topotecan and cytarabine in patients with refractory or relapsed AML or CML in blast crisis.

被引：0
|
作者：
Hoechsmann, B [1 ]
Döhner, H [1 ]
Ganser, A [1 ]
Heil, G [1 ]
Einsele, H [1 ]
Raghavachar, A [1 ]
Hoelzer, D [1 ]
Bergmann, L [1 ]
机构：
[1] Univ Ulm, Dept Hematol Oncol, Ulm, Germany
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1402
引用
收藏
页码：325A / 325A
页数：1
相关论文
共 50 条
  • [1] A multicentre trial with topotecan, mitoxantrone and cytarabine in patients with relapsed or refractory AML or CML in blast crisis - Interim results.
    Hoechsmann, B
    Doehner, H
    Ganser, A
    Heil, G
    Denzlinger, C
    Einsele, H
    Duerk, H
    Raghavachar, A
    Hoelzer, D
    Bergmann, L
    BLOOD, 2001, 98 (11) : 213B - 213B
  • [2] A new combination therapy with topotecan, cytarabine and mitoxantrone in patients with refractory or relapsed acute myeloid leukemia or blast crisis of chronic myeloid leukemia.
    Höchsmann, B
    Griesshammer, M
    Bergmann, L
    BLOOD, 1999, 94 (10) : 230B - 230B
  • [3] MITOXANTRONE AND 5-AZACYTIDINE FOR REFRACTORY RELAPSED ANLL OR CML IN BLAST CRISIS - A LEUKEMIA INTERGROUP STUDY
    GOLDBERG, J
    GRYN, J
    RAZA, A
    BENNETT, J
    BROWMAN, G
    BRYANT, J
    GRUNWALD, H
    LARSON, R
    VOGLER, R
    PREISLER, H
    AMERICAN JOURNAL OF HEMATOLOGY, 1993, 43 (04) : 286 - 290
  • [4] Outcome of patients with refractory/relapsed AML salvaged with the MEC (Mitoxantrone Etoposide Cytarabine) regimen.
    Castagnola, C
    Alessandrino, EP
    Pagnucco, G
    Bernasconi, P
    Lunghi, M
    Colombo, A
    Brusamolino, E
    Bonfichi, M
    Corso, A
    Lazzarino, M
    Bernasconi, C
    BLOOD, 2000, 96 (11) : 210B - 210B
  • [5] Combination of Cladribine, Cytarabine and Topotecan (CLAT) for Relapsed or Refractory Acute Myeloid Leukemia
    Chen, Xiaomei
    Weng, Jianyu
    Wang, Yulian
    Deng, Chengxin
    Luo, Chengwei
    Liao, Pengjun
    Li, Minming
    Huang, Xin
    Lai, Peilong
    Huang, Lisi
    Cao, Zhi
    Wan, Changchun
    Zhong, Liye
    Wu, Suijing
    Lu, Zesheng
    Zou, Xiaoli
    Du, Xin
    BLOOD, 2015, 126 (23)
  • [6] A phase I/II study of topotecan, mitoxantrone and etoposide in relapsed/refractory acute myeloid leukemia (AML), myeloid blast crisis and high risk myelodysplastic syndromes (MDS).
    Nand, S
    Stiff, P
    Beltran, O
    Godwin, J
    BLOOD, 1999, 94 (10) : 234B - 234B
  • [7] Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML
    Uy, Geoffrey L.
    Rettig, Michael P.
    Fletcher, Theresa
    Riedell, Peter A.
    Stockerl-Goldstein, Keith E.
    Ghobadi, Armin
    Jacoby, Meagan
    Cashen, Amanda F.
    Romee, Rizwan
    Pusic, Iskra
    Abboud, Camille N.
    Schroeder, Mark A.
    Vij, Ravi
    Westervelt, Peter
    DiPersio, John F.
    BLOOD, 2017, 130
  • [8] Interim Analysis of a Single Arm Phase II Study of Cpi-613 in Combination with High Dose Cytarabine and Mitoxantrone for Patients with Relapsed or Refractory AML
    Pardee, Timothy S.
    Isom, Scott
    Ellis, Leslie Renee
    Howard, Dianna S.
    Bhave, Rupali
    Manuel, Megan
    Dralle, Sarah
    Lyerly, Susan
    Powell, Bayard L.
    BLOOD, 2017, 130
  • [9] Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients
    Scappini, Barbara
    Gianfaldoni, Giacomo
    Caracciolo, Francesco
    Mannelli, Francesco
    Biagiotti, Caterina
    Romani, Claudio
    Pogliani, Enrico M.
    Simonetti, Federico
    Borin, Lorenza
    Fanci, Rosa
    Cutini, Ilaria
    Longo, Giovanni
    Susini, Maria Chiara
    Angelucci, Emanuele
    Bosi, Alberto
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (12) : 1047 - 1051
  • [10] A phase I/II study of induction therapy with topotecan, mitoxantrone and etoposide in relapsed/refractory acute myeloid leukemia (AML), myeloid blast crisis and high risk myelodysplastic syndromes (MDS).
    Nand, S
    Godwin, J
    White, C
    Beltran, O
    Stiff, P
    BLOOD, 2000, 96 (11) : 214B - 214B
12345